2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[H]quinoline-4-carboxylic acid (PSI-697):: Identification of a clinical candidate from the quinoline salicylic acid series of P-selectin antagonists

被引:72
作者
Kaila, Neelu [1 ]
Janz, Kristin [1 ]
Huang, Adrian [1 ]
Moretto, Alessandro [1 ]
DeBernardo, Silvano [1 ]
Bedard, Patricia W. [1 ]
Tam, Steve [1 ]
Clerin, Valerie [1 ]
Keith, James C., Jr. [1 ]
Tsao, Desiree H. H. [1 ]
Sushkova, Natalia [1 ]
Shaw, Gray D. [1 ]
Camphausen, Raymond T. [1 ]
Schaub, Robert G. [1 ]
Wang, Qin [1 ]
机构
[1] Wyeth Res, Chem & Screening Sci, Cardiovasc & Metab Dis, Drug Safety & Metab, Cambridge, MA 02140 USA
关键词
D O I
10.1021/jm060631p
中图分类号
R914 [药物化学];
学科分类号
100701 [药物化学];
摘要
P-selectin-PSGL-1 interaction causes rolling of leukocytes on the endothelial cell surface, which subsequently leads to firm adherence and leukocyte transmigration through the vessel wall into the surrounding tissues. P-selectin is upregulated on the surface of both platelets and endothelium in a variety of atherosclerosis-associated conditions. Consequently, inhibition of this interaction by means of a small molecule P-selectin antagonist is an attractive strategy for the treatment of atherosclerosis. High-throughput screening and subsequent analoging had led to the identification of compound 1 as the lead candidate. Herein, we report the continuation of this work and the discovery of a second-generation series, the tetrahydrobenzoquinoline salicylic acids. These compounds have improved pharmacokinetic properties, and a number of them have shown oral efficacy in mouse and rat models of atherogenesis and vascular injury. The lead 31 (PSI-697), is currently in clinical development for the treatment of atherothrombotic vascular events.
引用
收藏
页码:40 / 64
页数:25
相关论文
共 67 条
[1]
Selectin blockade prevents antigen-induced late bronchial responses and airway hyperresponsiveness in allergic sheep [J].
Abraham, WM ;
Ahmed, A ;
Sabater, JR ;
Lauredo, IT ;
Botvinnikova, Y ;
Bjercke, RJ ;
Hu, X ;
Revelle, BM ;
Kogan, TP ;
Scott, IL ;
Dixon, RAF ;
Yeh, ETH ;
Beck, PJ .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (04) :1205-1214
[2]
ACKERMAN NR, 1989, Patent No. 1989339485
[3]
Searching for medicine's sweet spot [J].
Alper, J .
SCIENCE, 2001, 291 (5512) :2338-2343
[4]
Arndt F, 1935, ORG SYNTH, V15, P3
[5]
Development of synthetic pan-selectin antagonists: A new treatment strategy for chronic inflammation in asthma [J].
Aydt, E ;
Wolff, G .
PATHOBIOLOGY, 2002, 70 (05) :297-301
[6]
BEDARD PW, UNPUB P INT SOC THRO
[7]
Inhibitors of membrane receptors involved with leukocute extravasation [J].
Bendas, G .
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2005, 5 (06) :575-584
[8]
Recombinant soluble P-selectin glycoprotein ligand-1-Ig reduces restenosis through inhibition of platelet-neutrophil adhesion after double angioplasty in swine [J].
Bienvenu, JG ;
Tanguay, JF ;
Théorêt, JF ;
Kumar, A ;
Schaub, RG ;
Merhi, Y .
CIRCULATION, 2001, 103 (08) :1128-1134
[9]
SYNTHESIS OF ANALOGS OF 1,3-DIHYDROXYACETONE PHOSPHATE AND GLYCERALDEHYDE-3-PHOSPHATE FOR USE IN STUDIES OF FRUCTOSE-1,6-DIPHOSPHATE ALDOLASE [J].
BISCHOFBERGER, N ;
WALDMANN, H ;
SAITO, T ;
SIMON, ES ;
LEES, W ;
BEDNARSKI, MD ;
WHITESIDES, GM .
JOURNAL OF ORGANIC CHEMISTRY, 1988, 53 (15) :3457-3465
[10]
The adhesion molecule P-selectin and cardiovascular disease [J].
Blann, AD ;
Nadar, SK ;
Lip, GYH .
EUROPEAN HEART JOURNAL, 2003, 24 (24) :2166-2179